소득공제
수입
직수입양서
Biotechnology Valuation
An Introductory Guide
Hardback, 1st Edition
Keegan, Karl
Wiley
2008.12.31.
- POD (Publish On Demand) 도서로 표지재질, 제본상태 등이 일반 도서와 차이가 있을 수 있습니다.
이미 소장하고 있다면 판매해 보세요.
- 국내배송만 가능
- 해외 거래처 사정에 의하여 품절/지연 가능
- 도서 정보 중 미표기 사항 안내?
- 문화비소득공제 가능
Wiley Finance Series
-
Damodaran on Valuation: Security Analysis for Investment and Corporate Finance 이동Damodaran on Valuation: Security Analysis for Investment and Corporate Finance60,000원 -
Active Index Investing: Global Index Strategies 이동Active Index Investing: Global Index Strategies18% 131,830원
-
Active Investment Management: Finding and Harnessing Investment Skill 이동Active Investment Management: Finding and Harnessing Investment Skill18% 153,890원
-
Hedge Funds: Definitive Strategies and Techniques 이동Hedge Funds: Definitive Strategies and Techniques18% 146,500원
-
Collateralized Debt Obligations and Structured Finance: New Developments in Cash and Synthetic Secur 이동Collateralized Debt Obligations and Structured Finance: New Developments in Cash and Synthetic Secur18% 131,910원
-
Fixed-Income Securities: Valuation, Risk Management and Portfolio Strategies 이동Fixed-Income Securities: Valuation, Risk Management and Portfolio Strategies50% 80,430원
-
Enterprise Risk Management : From Incentives to Controls 이동Enterprise Risk Management : From Incentives to Controls52,000원
-
Real Options Analysis Course: Business Cases and Software Applications 이동Real Options Analysis Course: Business Cases and Software Applications18% 438,250원
-
The Investor's Guide to Economic Fundamentals 이동The Investor's Guide to Economic Fundamentals18% 219,850원
-
Global Asset Allocation: New Methods and Applications 이동Global Asset Allocation: New Methods and Applications18% 115,710원
-
Currency Strategy: The Practitioner's Guide to Currency Investing, Hedging and Forecasting 이동Currency Strategy: The Practitioner's Guide to Currency Investing, Hedging and Forecasting80% 10,000원
책소개
목차
|
Acknowledgements xi 1 Introduction 1 Biotechnology Background 5 2 Traditional Valuation Methods 11 The Value of a Company 11 Accounts ? Providing the Data for Valuation Analysis 12 The Income Statement 13 Balance Sheet 17 Cash Flow Statement 20 Income Statement Multiples 22 Balance Sheet Multiples 26 Summary 27 Discounted Cash Flow Analysis 27 Net Present Value 27 Constructing the DCF 28 Projecting the Cash Flow Stream 29 Choosing a Discount Rate 30 Other Thoughts 37 3 The Drug Development Process 39 The Drug Development Process 40 Drug Discovery and Research 44 Pre-Clinical Development 44 Clinical Trials 48 What Investors Should Look For When Analysing Clinical Trials 56 Conclusion 59 The Regulatory Process 59 Regulation in the US 60 Regulation in Europe 63 The Label 64 Timelines for Approval 65 Post Approval 65 Investment Lessons 66 Case Study # 1 66 4 Biotechnology Company Valuation 69 Data Collation 71 NPV of the Pipeline 75 Calculations 80 Sensitivity Analyses 86 DCF of Whole Company 92 EBIT DCF of Products 97 Comparables Valuation 99 NPVs are Additive 101 Using all the Tools Available to Reach a Valuation Conclusion 101 Market Models 104 Conclusion 105 Appendix 1 106 Example 1 106 Example 2 108 Example 3 108 Appendix 2 116 Biosimilar Update 116 5 Decision Trees and Real Options 119 Decision Trees 120 Discount Rate 124 Deriving Scenarios 125 Conclusion 125 Decision Tree Example 126 Real Options 126 Valuing Options 129 Estimation of the Input Variables 138 Conclusions 139 6 Biotechnology Investing 141 Types of Healthcare Investment 141 Biotechnology Sector Evolution 143 Biotechnology Investment Cycles 145 Biotechnology Business Models 152 Focus on People 154 Cash 155 Product Pipeline 155 Commercial Risks 156 Newsflow 158 Lessons from Biotech Investing 160 7 Early-stage Valuation 161 Private Valuation 162 Discounted Cash Flow Method 166 Comparable Valuation 168 Venture Capital Method 170 Discount Rates 173 Conclusion 173 Glossary 175 References 189 Index 193 |
저자 소개
KARL KEEGAN is currently a managing director and global head of life sciences equity research at CanaccordAdams, a global investment bank focussing on small to mid cap companies. Karl has been a financial analyst covering the biotechnology sector for over eleven years and has previously worked at Dresdner Kleinwort Benson, UBS and Banc of America. Karl and his team have been consistently highly ranked in institutional surveys throughout his career. Prior to embarking on his finance career, Karl completed postdoctoral assignments in the US and UK and worked in the pharmaceutical industry both as a bench scientist and in strategic planning. Dr. Keegan holds a BSc in Pharmacology from University College Dublin, Ireland, MPhil and PhD degrees in Pharmacology from University of Cambridge, UK and MSc in Finance from London Business School, UK. A native of Dublin, Ireland, he now lives in Kent, UK.
품목정보
- 발행일
- 2008년 12월 31일
- 쪽수, 무게, 크기
- 224쪽 | 174*242*23mm
- ISBN13
- 9780470511787
리뷰/한줄평0
상품정보안내
직수입외서의 경우, 해외거래처에서 제공하는 정보가 부족하여 제목, 표지, 가격, 유통상태 등의 정보가 미비하거나 변경되는 경우가 있습니다. 정확한 확인을 원하시는 경우, 일대일 상담으로 문의하여 주시면 답변 드리겠습니다.
(판형과 판수 등이 다양한 도서는 찾으시는 도서의 ISBN을 알려 주시면 보다 빠르고 정확한 안내가 가능합니다.)
해외거래처에서 품절인 경우, 2차 거래선을 통해 유럽과 미국 출판사로 직접 수입이 진행될 수 있습니다.
수입 진행 시점으로 부터 2~3주가 추가로 소요되며, 해외에서도 유통이 원활하지 않은 도서는 품절 안내가 지연될 수 있습니다.
해당 경우, 문자와 메일로 별도 안내를 드리고 있사오니 마이페이지에서 휴대전화번호와 메일주소를 다시 한번 확인해주시기 바랍니다.
(판형과 판수 등이 다양한 도서는 찾으시는 도서의 ISBN을 알려 주시면 보다 빠르고 정확한 안내가 가능합니다.)
해외거래처에서 품절인 경우, 2차 거래선을 통해 유럽과 미국 출판사로 직접 수입이 진행될 수 있습니다.
수입 진행 시점으로 부터 2~3주가 추가로 소요되며, 해외에서도 유통이 원활하지 않은 도서는 품절 안내가 지연될 수 있습니다.
해당 경우, 문자와 메일로 별도 안내를 드리고 있사오니 마이페이지에서 휴대전화번호와 메일주소를 다시 한번 확인해주시기 바랍니다.
158,300원
총 1개
158,300원
